Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients - Sorbonne Université Accéder directement au contenu
Article Dans Une Revue Scientific Reports Année : 2016

Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients

Guillaume Corre
Wladimir Mauhin
Giuseppe Ronzitti
Francesco Puzzo
  • Fonction : Auteur
Pasqualina Colella

Résumé

Immunogenicity of recombinant human acid-alpha glucosidase (rhGAA) in enzyme replacement therapy (ERT) is a safety and efficacy concern in the management of late-onset Pompe disease (LOPD). However, long-term effects of ERT on humoral and cellular responses to rhGAA are still poorly understood. To better understand the impact of immunogenicity of rhGAA on the efficacy of ERT, clinical data and blood samples from LOPD patients undergoing ERT for >4 years (n = 28) or untreated (n = 10) were collected and analyzed. In treated LOPD patients, anti-rhGAA antibodies peaked within the first 1000 days of ERT, while long-term exposure to rhGAA resulted in clearance of antibodies with residual production of non-neutralizing IgG. Analysis of  T cell responses to rhGAA showed detectable T cell reactivity only after in vitro restimulation. Upregulation of several cytokines and chemokines was detectable in both treated and untreated LOPD subjects, while IL2 secretion was detectable only in subjects who received ERT. These results indicate that long-term ERT in LOPD patients results in a decrease in antibody titers and residual production of non-inhibitory IgGs. Immune responses to GAA following long-term ERT do not seem to affect efficacy of ERT and are consistent with an immunomodulatory effect possibly mediated by regulatory T cells.
Fichier principal
Vignette du fichier
srep36182.pdf (1.27 Mo) Télécharger le fichier
Origine : Publication financée par une institution
Loading...

Dates et versions

hal-01404918 , version 1 (29-11-2016)

Licence

Paternité

Identifiants

Citer

Elisa Masat, Pascal Laforêt, Marie de Antonio, Guillaume Corre, Barbara Perniconi, et al.. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients. Scientific Reports, 2016, 6, pp.36182. ⟨10.1038/srep36182⟩. ⟨hal-01404918⟩
783 Consultations
159 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More